References
- Stoll D, Cines DB, Aster RH, Murphi S. Platelet kinetics with idiopathic thrombocytopenic purpura and moderate thrombocytopenia. Blood. 1985;65:584–8.
- Ballem PJ, Segal GM, Stratton JR, Gernsheimer T, Adamson JW, Slichter SJ. Mechanism of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. J Clin Invest. 1987;80:33–40.
- McMillian R, Wang L, Tomer A, Nichol J, Pistillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood. 2004;103:1364–9.
- Nugent D, McMillian R, Nichol JL, Slichter SJ. Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production. Br J Haematol. 2009;146(6):585–96.
- McMillian R, Nugent D. The effect of antiplatelet autoantibodies on megakaryocytopoiesis. Int J Hematol. 2005;81(2):94–9.
- Liebman HA, Pullarkat V. Diagnosis and management of immune thrombocytopenia in the era of thrombopoietin mimetics. Hematology Am Soc Hematol Educ Program. 2011;2011:384–90.
- Gebauer E, Vijatov G. Idiopathic thrombocytopenic purpura in children. Med Pregl. 1998;51(3–4):127–34.
- Blanchette V, Bolton-Maggs P. Childhood immune thrombocytopenic purpura: diagnosis and management. Pediatr Clin North Am. 2008;55(2):393–420, ix.
- McMillian R. Antiplatelet antibodies in chronic immune thrombocytopenia and their role in platelet destruction and defective production. Hematol Oncol Clin North Am. 2009;23(6):1163–75.
- Imbach P, Tani P, Berchtold W, Blanchette V, Burek-Kozlowsca A, Gerber H, et al. Different form of chronic childhood thrombocytopenic purpura defined by antiplatelet autoantibodies. J Pediatr. 1991;118:535–9.
- Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITp syndrome: a diverse set of disorders with different immune mechanisms. Blood. 2009;113:6511–21.
- Semple JW. Infections, antigen-presenting cells, T cells, and immune tolerance: their role in the pathogenesis of immune thrombocytopenia. Hematol Onco Clin North Am. 2009;23(6):1177–1192.
- Olsson B, Andersson P, Jernas M, Jacobsson S, Carlsson LM, Wadenvik H. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med. 2003;9:1123–4.
- McMillion R. Autoantibodies and autoantigens in chronic immune thrombocytopenic purpura. Semin Hematol. 2000;37(3):239–48.
- Houwerzijl EJ, Blom NR, van der Want JJL, Esselink MT, Koornstra JJ, Smit JW, et al. Ultrastructural study shows morphological features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood. 2004;103:500–6.
- Kuter DJ, Gernsheimer TB. Thrombopoietin and platelet production in chronic immune thrombocytopenia. Hematol Oncol Clin North Am. 2009;23:1193–211.
- Nichol JL. Thrombopoietin levels after chemotherapy and in naturally occurring human diseases. Curr Opin Hematol. 1998;5:203–8.
- Bussel JB, Cheng G, Saleh MN, Mayer B, Vasey SY. Incidence of thromboembolic events across eltrombopag clinical trials in chronic immune thrombocytopenia (ITP). Blood. 2010;116:70.
- Kashif M, Qureshi A, Adil SN, Khurshid M. Successful use of rituximab in Evans syndrome and refractory immune thrombocytopenic purpura. J Pak Med Assoc. 2010;60(1):64–5.
- Borker A, Choundhary N. Rituximab. Indian Pediatr. 2011;48(8):627–32.
- Newland AC, Treleaven JG, Minchinton RM, Waters AH. High-dose intravenous IgG in adults with autoimmune thrombocytopenia. Lancet. 1983;1:84–7.
- Arnold DM, Dentali F, Crowther MA, Meyer MR, Cook RJ, Sigouin C, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med. 2007;146:25–33.